Abcam, ab247765, Anti-NAT1 antibody [EPR3221(2)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal NAT1 antibody. Carrier free. Suitable for ICC/IF, WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR3221(2),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:ICC/IF, WB, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab247765 is the carrier-free version of
ab109114
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please
contact us
for more information.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
NAT1 also known as arylamine N-acetyltransferase 1 serves as an important enzyme in acetylation reactions. This enzyme with a molecular mass of approximately 33 kDa catalyzes the transfer of acetyl groups to arylamines and other substrates such as hydrazines. By doing so NAT1 influences xenobiotic metabolism. The enzyme is expressed in various tissues most notably in the liver intestine and lung which aligns with its role in detoxifying and metabolizing drugs and carcinogens.
Biological function summary
NAT1 plays a significant role in detoxifying environmental toxins and carcinogens. The enzyme's activity contributes to the acetylation a phase II metabolic reaction which often converts lipophilic substrates into more hydrophilic products for excretion. NAT1 stands independently and does not form part of a larger complex. It shares functional similarities with other N-acetyltransferases but its substrate specificity can differ which influences its distinct biological role.
Pathways
NAT1 is intricately involved in metabolic and detoxification pathways. It participates in the biotransformation of various drugs and environmental carcinogens making it important for xenobiotic metabolism. NAT1 often interacts with cytochrome P450 enzymes during these processes which also contribute to the initial phase I oxidation reactions. The interplay between NAT1 and these detoxification pathways highlights the enzyme's contribution to reducing potential toxicities.
NAT1 has associations with both cancer and hypersensitivity to certain drugs. Variations in NAT1 activity due to genetic polymorphisms can influence individual susceptibility to cancers particularly bladder cancer linked to arylamine exposure. Additionally its interaction with cytochrome P450 enzymes may also impact drug metabolism potentially leading to adverse drug reactions. Understanding NAT1 and its interactions help assess risks related to these diseases.